IRON
Disc Medicine, Inc.
NASDAQ · Healthcare · Biotechnology · US
$83.12
+2.42%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$81.50
From 52W high−11.67%
Volume206566.00
Market cap$3.69B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$81.50
From 52W high
−11.67%
Volume
206566.00
Market cap
$3.69B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−12.6x
P/E (TTM)
—
RSI (14)
65.1
MomentumView details →
1D Return
+2.42%
YTD Return
+3.99%
SummaryUpdated Jun 1, 2026
Disc Medicine, Inc. (NASDAQ:IRON) is a clinical-stage biotechnology company founded and based in Watertown, Massachusetts. The company went public in August 2020 and focuses on developing novel treatments for patients suffering from serious blood disorders, specifically hematologic diseases. Disc Medicine builds its therapeutic pipeline by targeting fundamental biological pathways related to red blood cell biology, with particular emphasis on heme biosynthesis and iron homeostasis - the processes by which the body produces red blood cells and manages iron levels.
Similar companies
Latest newsMore news →
Disc Medicine, Inc. announced pricing of an underwritten public offering of 6,000,000 common shares at $75 per share, with expected gross proceeds of $450 million before expenses, excluding any exercise of the underwriters’ option.15d agoDisc Medicine, Inc. announced the commencement of an underwritten public offering of $350 million of common stock and, for certain investors, pre-funded warrants to purchase common stock.16d agoDisc Medicine, Inc. shares rose 34.92% to $76.69 during U.S. trading.16d ago